Routine prophylaxis with proton pump inhibitors and post-transplant complications in kidney transplant recipients undergoing early corticosteroid withdrawal

Clinical Transplantation

Volumn 30, Issue 6, 2016, Pages 694-702

  Courson, Alesa Y ^a,b   Lee, John R ^a   Aull, Meredith J ^a   Lee, Jennifer H ^a   Kapur, Sandip ^a   McDermott, Jennifer K ^a,c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c SPECTRUM HEALTH   (United States)

Author keywords

infection; kidney transplantation; rejection; safety

Indexed keywords

CORTICOSTEROID; MYCOPHENOLATE MOFETIL; PROTON PUMP INHIBITOR; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; COHORT ANALYSIS; DIGESTIVE SYSTEM ULCER; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; ADOLESCENT; ADVERSE EFFECTS; CLINICAL TRIAL; GRAFT REJECTION; POSTOPERATIVE COMPLICATION; TREATMENT WITHDRAWAL; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TRANSPLANT RECIPIENTS; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84964655274     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12736     Document Type: Article

References (47)

1. Ardalan MR, Etemadi J, Somi MH et al. Upper gastrointestinal bleeding during the first month after renal transplantation in the mycophenolate mofetil era. Transplant Proc 2009: 41: 2845.
2. Troppman C, Papalois BE, Chiou A et al. Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. J Am Coll Surg 1995: 180: 433.
3. Telkes G, Peter A, Tulassay Z et al. High frequency of ulcers, not associated with Helicobacter pylori, in the stomach in the first year after kidney transplantation. Nephrol Dial Transplant 2011: 26: 727.
4. Gil-Vernet S, Amado A, Ortega F et al. Gastrointestinal complications in renal transplant recipients: MITOS study. Transplant Proc 2007: 39: 2190.
5. Walter S, Thorup Andersen J, Christensen U et al. Effect of cimetidine on upper gastrointestinal bleeding after renal transplantation. Br Med J 1984: 289: 1175.
6. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2011 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2011.
7. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol 2013: 6: 443.
8. Thomson ABR, Sauve MD, Kassam N et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010: 16: 2323.
9. de Jager CPC, Wever PC, Gemen EFA et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther 2012: 36: 941.
10. Meijvis SCA, Cornips MCA, Voorn GP et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. Eur Respir J 2011: 38: 1165.
11. Laheij RJF, Sturkenboom MCJ, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004: 292: 1955.
12. U.S. Food and Drug Administration. Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). February 8, 2012. Retrieved September 2, 2013 from http://www.fda.gov/drugs/drugsafety/ucm290510.htm.
13. Reveles KR, Lee GC, Boyd NK et al. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States. Am J Infect Control 2014: 42: 1028.
14. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010: 31: 431.
15. Lim WS, Baudouin SV, George RC et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009: 64 (Suppl III): iii1.
16. Dubberke ER, Burdette SD. Clostridium difficile infections in solid organ transplantation. Am J Transplant 2013: 13: 42.
17. Sileri P, Pursell KJ, Coady NT et al. A standardized protocol for the treatment of severe pneumonia in kidney transplant recipients. Clin Transplant 2002: 16: 450.
18. Cote GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008: 10: 208.
19. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Adverse risks associated with proton pump inhibitors: a systematic review. J Gastroenterol Hepatol 2009: 5: 725.
20. Kofler S, Shvets N, Bigdeli AK et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients – a prospective case-controlled study. Am J Transplant 2009: 9: 1650.
21. Doesch AO, Mueller S, Konstandin M et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc 2010: 42: 4243.
22. Gabardi S, Olyaei A. Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors. Ann Pharmacother 2012: 46: 1054.
23. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 2010: 49: 509.
24. Schaier M, Scholl C, Scharpf D et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology 2010: 49: 2061.
25. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014: 37: 201.
26. Early DS, Ben-Menachem T, Decker GA et al. Appropriate use of GI endoscopy: a consensus statement from the American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 2012: 75: 1127.
27. Sis B, Mengel M, Haas M et al. Banff ‘09 meeting report: antibody mediated graft deterioration and implementation of banff working groups. Am J Transplant 2010: 10: 464.
28. Red Book Online [database online]. Greenwood Village, CO: Truven Health Analytics, Inc. Updated periodically. Accessed December 20, 2015.
29. Sarkio S, Halme L, Kyllonen L et al. Severe gastrointestinal complications after 1,515 adult kidney transplantations. Transpl Int 2004: 17: 505.
30. Meyers WC, Harris N, Stein S et al. Alimentary tract complications after renal transplantation. Ann Surg 1979: 190: 535.
31. Deshpande A, Pant C, Pasupuleti V et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012: 10: 225.
32. Eom CS, Jeon CY, Lim JW et al. Use of acid-suppressive drugs and risk of pneumonia: systematic review and meta-analysis. CMAJ 2011: 183: 310.
33. Gabutti L, Stoller R, Vogt B. Omeprazole-induced agranulocytosis in a kidney transplant recipient. Nephrol Dial Transplant 1999: 14: 523.
34. Watson TD, Stark JE, Vesta KS. Pantoprazole-induced thrombocytopenia. Ann Pharmacother 2006: 40: 758.
35. Gouraud A, Vochelle V, Descotes J et al. Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole. Clin Drug Investig 2010: 30: 559.
36. Knorr JP, Sjeime M, Braitman LE et al. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation 2014: 97: 518.
37. van Boekel GAJ, Kerkhofs CHH, van de Logt F et al. Proton pump inhibitors do not increase the risk of acute rejection. Neth J Med 2014: 72: 86.
38. Bullingham R, Shah J, Goldblum R et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996: 41: 513.
39. Rupprecht K, Schmidt C, Raspe A et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol 2009: 49: 1196.
40. Li W, Zeng S, Yu LS et al. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag 2013: 9: 259.
41. David-Neto E, Takaki KM, Agena F et al. Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. Ther Drug Monit 2012: 34: 331.
42. Kees MG, Steinke T, Moritz S et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol 2012: 52: 1265.
43. Kofler S, Wolf C, Shvets N et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant 2011: 30: 565.
44. Hardinger KL, Brennan DC, Lowell J et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004: 17: 609.
45. Neri L, Rocca Rey LA, Pinsky BW et al. Increased risk of graft failure in kidney transplant recipients after a diagnosis of dyspepsia or gastroesophageal reflux disease. Transplantation 2008: 85: 344.
46. Bunnapradist S, Lentine KL, Burroughs TE et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006: 82: 102.
47. Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant 2011: 11: 2279.